Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onapristone ER with Letrozole and Palbociclib in ER+ MBC
NCT04872608Phase 1Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2021
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of onapristone extended release in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Recommended Phase 2 Dose at 1 year. Planned start Sep 2021; status: withdrawn.
02
Drugs
onapristone extended release
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04872608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872608.